Quercetin prevents left ventricular hypertrophy in the Apo E knockout mouse

Redox Biology

Volumn 1, Issue 1, 2013, Pages 381-386

  Ulasova, Elena ^a,b   Perez, Jessica ^b   Hill, Bradford G ^a,b   Bradley, Wayne E ^c   Garber, David W ^d   Landar, Aimee ^a,b   Barnes, Stephen ^b,e   Prasain, Jeevan ^e   Parks, Dale A ^b,f   Dell'Italia, Louis J ^c,d,g   Darley Usmar, Victor M ^a,c,g  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d University of Alabama at Birmingham   (United States)

^e University of Alabama at Birmingham   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

Atherosclerosis; Cholesterol; Hypertrophy; Quercetin

Indexed keywords

APOLIPOPROTEIN E; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; QUERCETIN; VERY LOW DENSITY LIPOPROTEIN; ANTIOXIDANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG BLOOD LEVEL; FOOD COMPOSITION; HEART FUNCTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART RATE; HEMODYNAMIC PARAMETERS; HYPERCHOLESTEROLEMIA; KNOCKOUT MOUSE; LIQUID CHROMATOGRAPHY; LOW DRUG DOSE; MEAN ARTERIAL PRESSURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TANDEM MASS SPECTROMETRY; TREATMENT OUTCOME; WILD TYPE; ANIMAL; BLOOD; C57BL MOUSE; COMPLICATION; DIET THERAPY; DRUG EFFECTS; GENETICS; HEART VENTRICLE REMODELING; PATHOLOGY; PATHOPHYSIOLOGY;

MUS;

ANIMALS; ANTIOXIDANTS; APOLIPOPROTEINS E; CHOLESTEROL; HYPERCHOLESTEROLEMIA; HYPERTROPHY, LEFT VENTRICULAR; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; QUERCETIN; VENTRICULAR REMODELING;

EID: 84881247580     PISSN: 22132317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.redox.2013.07.001     Document Type: Article

References (38)

1. Celentano A., Crivaro M., Roman M.J., Pietropaolo I., Greco R., Pauciullo P., Lirato C., Devereux R.B., de Simone G. Left ventricular geometry and arterial function in hypercholesterolemia. Nutrition, Metabolism and Cardiovascular Diseases 2001, 11:312-319.
2. Sundstrom J., Lind L., Vessby B., Andren B., Aro A., Lithell H. Dyslipidemia and an unfavorable fatty acid profile predict left ventricular hypertrophy 20 years later. Circulation 2001, 103:836-841.
3. Plump A.S., Smith J.D., Hayek T., Aalto-Setala K., Walsh A., Verstuyft J.G., Rubin E.M., Breslow J.L. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 1992, 71:343-353.
4. Yang R., Powell-Braxton L., Ogaoawara A.K., Dybdal N., Bunting S., Ohneda O., Jin H. Hypertension and endothelial dysfunction in apolipoprotein E knockout mice. Arteriosclerosis, Thrombosis, and Vascular Biology 1999, 19:2762-2768.
5. Dadakova E., Prochazkova E., Krizek M. Application of micellar electrokinetic capillary chromatography for quantitative analysis of quercetin in plant materials. Electrophoresis 2001, 22:1573-1578.
6. Qin T.C., Chen L., Yu L.X., Gu Z.L. Inhibitory effect of quercetin on cultured neonatal rat cardiomyocytes hypertrophy induced by angiotensin. Acta Pharmacologica Sinica 2001, 22:1103-1106.
7. Jalili T., Carlstrom J., Kim S., Freeman D., Jin H., Wu T.C., Litwin S.E., David Symons J. Quercetin-supplemented diets lower blood pressure and attenuate cardiac hypertrophy in rats with aortic constriction. Journal of Cardiovascular Pharmacology 2006, 47:531-541.
8. Juric D., Wojciechowski P., Das D.K., Netticadan T. Prevention of concentric hypertrophy and diastolic impairment in aortic-banded rats treated with resveratrol. American Journal of Physiology-Heart and Circulatory Physiology 2007, 292:H2138-2143.
9. Cheng T.H., Liu J.C., Lin H., Shih N.L., Chen Y.L., Huang M.T., Chan P., Cheng C.F., Chen J.J. Inhibitory effect of resveratrol on angiotensin II-induced cardiomyocyte hypertrophy. Naunyn-Schmiedeberg's Archives of Pharmacology 2004, 369:239-244.
10. Kay C.D., Hooper L., Kroon P.A., Rimm E.B., Cassidy A. Relative impact of flavonoid composition, dose and structure on vascular function: a systematic review of randomised controlled trials of flavonoid-rich food products. Molecular Nutrition and Food Research 2012, 56:1605-1616.
11. Arai Y., Watanabe S., Kimira M., Shimoi K., Mochizuki R., Kinae N. Dietary intakes of flavonols, flavones and isoflavones by Japanese women and the inverse correlation between quercetin intake and plasma LDL cholesterol concentration. Journal of Nutrition 2000, 130:2243-2250.
12. Zern T.L., West K.L., Fernandez M.L. Grape polyphenols decrease plasma triglycerides and cholesterol accumulation in the aorta of ovariectomized guinea pigs. Journal of Nutrition 2003, 133:2268-2272.
13. Kamada C., da Silva E.L., Ohnishi-Kameyama M., Moon J.H., Terao J. Attenuation of lipid peroxidation and hyperlipidemia by quercetin glucoside in the aorta of high cholesterol-fed rabbit. Free Radical Research 2005, 39:185-194.
14. Lara-Guzman O.J., Tabares-Guevara J.H., Leon-Varela Y.M., Alvarez R.M., Roldan M., Sierra J.A., Londono-Londono J.A., Ramirez-Pineda J.R. Proatherogenic macrophage activities are targeted by the flavonoid quercetin. The Journal of Pharmacology and Experimental Therapeutics 2012, 343:296-306.
15. He T., Chen L., Chen Y., Han Y., Yang W.Q., Jin M.W. In vivo and in vitro protective effects of pentamethylquercetin on cardiac hypertrophy. Cardiovascular Drugs and Therapy 2012, 26:109-120.
16. Loke W.M., Proudfoot J.M., Hodgson J.M., McKinley A.J., Hime N., Magat M., Stocker R., Croft K.D. Specific dietary polyphenols attenuate atherosclerosis in apolipoprotein E-knockout mice by alleviating inflammation and endothelial dysfunction. Arteriosclerosis, Thrombosis and Vascular Biology 2010, 30:749-757.
17. Brookes P.S., Digerness S.B., Parks D.A., Darley-Usmar V. Mitochondrial function in response to cardiac ischemia-reperfusion after oral treatment with quercetin. Free Radical Biology and Medicine 2002, 32:1220-1228.
18. Garber D.W., Kulkarni K.R., Anantharamaiah G.M. A sensitive and convenient method for lipoprotein profile analysis of individual mouse plasma samples. Journal of Lipid Research 2000, 41:1020-1026.
19. Wang Y.X., Halks-Miller M., Vergona R., Sullivan M.E., Fitch R., Mallari C., Martin-McNulty B., da Cunha V., Freay A., Rubanyi G.M., Kauser K. Increased aortic stiffness assessed by pulse wave velocity in apolipoprotein E-deficient mice. American Journal of Physiology Heart and Circulatory Physiology 2000, 278:H428-434.
20. Wolfle S.E., de Wit C. Intact endothelium-dependent dilation and conducted responses in resistance vessels of hypercholesterolemic mice in vivo. Journal of Vascular Research 2005, 42:475-482.
21. Manach C., Mazur A., Scalbert A. Polyphenols and prevention of cardiovascular diseases. Current Opinion in Lipidology 2005, 16:77-84.
22. Sundstrom J., Riserus U., Byberg L., Zethelius B., Lithell H., Lind L. Clinical value of the metabolic syndrome for long term prediction of total and cardiovascular mortality: prospective, population based cohort study. British Medical Journal 2006, 332:878-882.
23. Cherniack E.P. Polyphenols: planting the seeds of treatment for the metabolic syndrome. Nutrition 2011, 27:617-623.
24. Fremont L., Gozzelino M.T., Linard A. Response of plasma lipids to dietary cholesterol and wine polyphenols in rats fed polyunsaturated fat diets. Lipids 2000, 35:991-999.
25. Allen R.R., Carson L., Kwik-Uribe C., Evans E.M., Erdman J.W. Daily consumption of a dark chocolate containing flavanols and added sterol esters affects cardiovascular risk factors in a normotensive population with elevated cholesterol. Journal of Nutrition 2008, 138:725-731.
26. Covas M.I., Fito M., Lamuela-Raventos R.M., Sebastia N., de la Torre-Boronat C., Marrugat J. Virgin olive oil phenolic compounds: binding to human low density lipoprotein (LDL) and effect on LDL oxidation. International Journal of Clinical Pharmacology Research 2000, 20:49-54.
27. Hakamata H., Sakaguchi H., Zhang C., Sakashita N., Suzuki H., Miyazaki A., Takeya M., Takahashi K., Kitamura N., Horiuchi S. The very low- and intermediate-density lipoprotein fraction isolated from apolipoprotein E-knockout mice transforms macrophages to foam cells through an apolipoprotein E-independent pathway. Biochemistry 1998, 37:13720-13727.
28. Stollenwerk M.M., Lindholm M.W., Porn-Ares M.I., Larsson A., Nilsson J., Ares M.P. Very low-density lipoprotein induces interleukin-1beta expression in macrophages. Biochemical and Biophysical Research Communications 2005, 335:603-608.
29. Stollenwerk M.M., Schiopu A., Fredrikson G.N., Dichtl W., Nilsson J., Ares M.P. Very low density lipoprotein potentiates tumor necrosis factor-alpha expression in macrophages. Atherosclerosis 2005, 179:247-254.
30. Mensenkamp A.R., Jong M.C., van Goor H., van Luyn M.J., Bloks V., Havinga R., Voshol P.J., Hofker M.H., van Dijk K.W., Havekes L.M., Kuipers F. Apolipoprotein E participates in the regulation of very low density lipoprotein-triglyceride secretion by the liver. Journal of Biological Chemistry 1999, 274:35711-35718.
31. Maugeais C., Tietge U.J., Tsukamoto K., Glick J.M., Rader D.J. Hepatic apolipoprotein E expression promotes very low density lipoprotein-apolipoprotein B production in vivo in mice. Journal of Lipid Research 2000, 41:1673-1679.
32. Medh J.D., Fry G.L., Bowen S.L., Ruben S., Wong H., Chappell D.A. Lipoprotein lipase- and hepatic triglyceride lipase- promoted very low density lipoprotein degradation proceeds via an apolipoprotein E-dependent mechanism. Journal of Lipid Research 2000, 41:1858-1871.
33. Duarte J., Perez-Palencia R., Vargas F., Ocete M.A., Perez-Vizcaino F., Zarzuelo A., Tamargo J. Antihypertensive effects of the flavonoid quercetin in spontaneously hypertensive rats. British Journal of Pharmacology 2001, 133:117-124.
34. Garcia-Saura M.F., Galisteo M., Villar I.C., Bermejo A., Zarzuelo A., Vargas F., Duarte J. Effects of chronic quercetin treatment in experimental renovascular hypertension. Molecular and Cellular Biochemistry 2005, 270:147-155.
35. Sanchez M., Galisteo M., Vera R., Villar I.C., Zarzuelo A., Tamargo J., Perez-Vizcaino F., Duarte J. Quercetin downregulates NADPH oxidase, increases eNOS activity and prevents endothelial dysfunction in spontaneously hypertensive rats. Journal of Hypertension 2006, 24:75-84.
36. Manach C., Morand C., Crespy V., Demigne C., Texier O., Regerat F., Remesy C. Quercetin is recovered in human plasma as conjugated derivatives which retain antioxidant properties. FEBS Letters 1998, 426:331-336.
37. Russo M., Spagnuolo C., Tedesco I., Bilotto S., Russo G.L. The flavonoid quercetin in disease prevention and therapy: facts and fancies. Biochemical Pharmacology 2012, 83:6-15.
38. Mao Z., Liang Y., Du X., Sun Z. 3,3',4',5,7-Pentamethylquercetin reduces angiotensin II-induced cardiac hypertrophy and apoptosis in rats. Canadian Journal of Physiology and Pharmacology 2009, 87:720-728.